The Indisputable Case for AI in Pharmacovigilance - Qinecsa

The Indisputable Case for AI in Pharmacovigilance

Ongoing drug safety monitoring is critical to containing risk and keeping patients safe, and with so many channels for reporting adverse events, the workload in processing cases is rising exponentially. But fit-for-purpose PV isn’t just about absorbing those extra volumes without driving up costs; it is also about maximising the positive impact of products for patients. This is especially true as ambitious new therapies enter markets with less predictable outcomes and side-effects over time. These converging requirements make harnessing AI non-negotiable, says Qinecsa’s Adam Sherlock.

Read article

Recent Articles

The Productivity Crisis That Persists Even Now: What Will It Take to Free Up PV Professionals to Assess Safety, Rather Than Coordinate Data?

Embracing quantitative signal detection methods as a smaller MAH

Real-Time Safety Signals Drive Continuous PV Insight

From Complaint Handling to Active Surveillance

Continuous Safety Surveillance for Medical Devices

Are patient outcomes getting lost in safety data complexity?

PreviousDigital Transformation Themes of 2025

NextLeaders in Pharma: 2026 predictions